Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease
Autor: | Bogdan Stankovic, Khosrow Adeli, Danielle Alvares, Simon Hoffman |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
endocrine system medicine.medical_specialty Lipoproteins Glucagon-Like Peptides 030209 endocrinology & metabolism digestive system Glucagon-Like Peptide-1 Receptor Pathogenesis 03 medical and health sciences 0302 clinical medicine Insulin resistance Glucagon-Like Peptide 1 Non-alcoholic Fatty Liver Disease Internal medicine medicine Glucagon-Like Peptide 2 Humans Molecular Biology business.industry Lipogenesis digestive oral and skin physiology Metabolic disorder Fatty liver nutritional and metabolic diseases Lipid metabolism Cell Biology Liraglutide medicine.disease Lipid Metabolism Lipids digestive system diseases 030104 developmental biology Endocrinology Liver Glucagon-Like Peptide-2 Receptor Exenatide Steatohepatitis Insulin Resistance business Peptides Lipoprotein Signal Transduction |
Zdroj: | Biochimica et biophysica acta. Molecular and cell biology of lipids. 1864(3) |
ISSN: | 1879-2618 |
Popis: | Non-alcoholic fatty liver disease (NAFLD) is a continuum of disorders that can range from simple steatosis to non-alcoholic steatohepatitis (NASH). As a complex metabolic disorder, the pathophysiology of NAFLD is incompletely understood. Recently glucagon-like peptide (GLP)-1 and -2 signalling has been implicated in the pathogenesis of NAFLD. The role of these gut hormones in the hepatic abnormalities is complicated by lack of consensus on the presence of GLP-1 and GLP-2 receptors within the liver. Nevertheless, GLP-1 and GLP-2 receptor agonists have been associated with alterations in lipid metabolism and hepatic and systemic inflammation, pathological abnormalities characteristic of NAFLD. Treatment with GLP-1 analogues has been shown to reverse features of NAFLD including insulin resistance, and alterations in hepatic de novo lipogenesis and reactive oxygen species. In this review, we provide an overview of the role of GLP-1 and GLP-2 in lipid homeostasis and metabolic disease including NAFLD and NASH. |
Databáze: | OpenAIRE |
Externí odkaz: |